Well, no sooner do I mention that Pfizer has a PCSK9 antibody coming along in the clinic then they don’t. Not any more. The company has announced that they’re discontinuing bococizumab, which comes as a surprise to most everyone, since they’d been spending substantial time and money on it. The company has concluded that it’s “not likely to provide value to patients, physicians, or shareholders“, because it appears that the immune response to the antibody gradually decreases its effectiveness. They’re also seeing more injection-site problems, which goes along with the first observation. The problems, they say, are definitely worse than the other agents in this class.
And that really leaves them nowhere to go on this one. If you’ve proven that the efficacy is lower and the side effects are higher, versus two direct competitors who are already on the market, the game is most surely over. They had, though, made it through at least four of the planned six (!) Phase III trials, eventually to include 17,000 patients, which should tell you just what a joy it is to work in the cardiovascular field. Always has been one, to be honest about it, and Pfizer knows that as well as anyone.